Madrigal Pharmaceuticals, Inc. (MDGL) |
|
150.02 1.07 (0.72%)
|
09-27 10:50 |
|
Open: |
149.45 |
Pre. Close: |
148.95 |
|
High:
|
153.52 |
Low:
|
149.2 |
|
Volume:
|
42,482 |
Market Cap:
|
2,771(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:17:57 AM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 208.95 One year: 234.32 |
| Support: |
Support1: 143.75 Support2: 119.6 |
| Resistance: |
Resistance1: 178.89 Resistance2: 200.61 |
| Pivot: |
169.92  |
| Moving Average: |
MA(5): 152.67 MA(20): 173.09
MA(100): 219.96 MA(250): 206.13  |
| MACD: |
MACD(12,26): -9.6 Signal(9): -7 |
| Stochastic oscillator: |
%K(14,3): 8.1 %D(3): 5.7 |
| RSI: |
RSI(14): 32.7 |
| 52-week: |
High: 322.67 Low: 57.2 |
| Average Vol(K): |
3-Month: 293 (K) 10-Days: 396 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MDGL ] has closed above bottom band by 18.8%. Bollinger Bands are 66% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
154.05 - 155.53 |
155.53 - 156.42 |
|
Low:
|
140.71 - 142.58 |
142.58 - 143.71 |
|
Close:
|
146.76 - 149.87 |
149.87 - 151.75 |
|
Company Description |
|
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. |
Headline News |
Wed, 27 Sep 2023
Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93 ... - The Motley Fool
Tue, 26 Sep 2023
Commit To Purchase Madrigal Pharmaceuticals At $140, Earn 32.4 ... - Nasdaq
Mon, 25 Sep 2023
Madrigal Pharma chief commercial officer leaving; shares down 3% - Seeking Alpha
Thu, 21 Sep 2023
Notable Thursday Option Activity: NET, SMCI, MDGL - Nasdaq
Thu, 21 Sep 2023
Weight-Loss Drugs Are Bad News for These Stocks - Barrons - Barron's
Wed, 20 Sep 2023
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
18 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
9.8 (%) |
|
% Held by Institutions
|
85 (%) |
|
Shares Short
|
1,960 (K) |
|
Shares Short P.Month
|
1,830 (K) |
Stock Financials |
|
EPS
|
-18.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.61 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-79.7 |
|
Return on Equity (ttm)
|
-352.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-17.87 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-277 (M) |
|
Levered Free Cash Flow
|
-156 (M) |
Stock Valuations |
|
PE Ratio
|
-8.18 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
26.85 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-10.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
